| Market Cap | 3.04B | P/E | - | EPS this Y | -33.60% | Ern Qtrly Grth | - |
| Income | -54.88M | Forward P/E | -34.56 | EPS next Y | -37.70% | 50D Avg Chg | 9.00% |
| Sales | 280.91M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 14.00% |
| Dividend | N/A | Price/Book | 11.59 | EPS next 5Y | - | 52W High Chg | -5.00% |
| Recommedations | 1.60 | Quick Ratio | 4.97 | Shares Outstanding | 50.02M | 52W Low Chg | 69.00% |
| Insider Own | 5.24% | ROA | -5.89% | Shares Float | 41.83M | Beta | 0.73 |
| Inst Own | 95.79% | ROE | -15.43% | Shares Shorted/Prior | 8.46M/5.92M | Price | 65.67 |
| Gross Margin | 28.88% | Profit Margin | -19.54% | Avg. Volume | 210,808 | Target Price | 80.87 |
| Oper. Margin | -21.24% | Earnings Date | Nov 5 | Volume | 196,184 | Change | -1.40% |
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.